Life Science Investing Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies 08 December
Life Science Investing Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia 02 December
Life Science Investing Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences 01 December
